Capital Fund Management S.A. Cuts Position in 10x Genomics $TXG

Key Points

• Capital Fund Management S.A. has reduced its stake in 10x Genomics by 10.0% in the first quarter, now owning 274,461 shares valued at approximately $2.4 million.
• 10x Genomics reported earnings of $0.28 per share for the last quarter, significantly surpassing analysts' estimates of a loss of $0.35 per share, with revenues up 12.9% year-over-year.
• Several institutional investors have increased their holdings in 10x Genomics, contributing to a total institutional ownership of 84.68%.

Capital Fund Management S.A. lessened its position in 10x Genomics (NASDAQ:TXG - Free Report) by 10.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 274,461 shares of the company's stock after selling 30,371 shares during the quarter. Capital Fund Management S.A. owned about 0.22% of 10x Genomics worth $2,396,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC lifted its position in shares of 10x Genomics by 81.8% in the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after acquiring an additional 1,614 shares during the period. Xponance Inc. increased its holdings in shares of 10x Genomics by 17.4% in the first quarter. Xponance Inc. now owns 12,010 shares of the company's stock valued at $105,000 after purchasing an additional 1,778 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in 10x Genomics during the 4th quarter worth about $32,000. Signaturefd LLC lifted its stake in shares of 10x Genomics by 134.3% in the 1st quarter. Signaturefd LLC now owns 4,203 shares of the company's stock valued at $37,000 after purchasing an additional 2,409 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of 10x Genomics by 9.0% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 31,061 shares of the company's stock valued at $271,000 after acquiring an additional 2,564 shares during the period. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at 10x Genomics

In related news, CFO Adam Taich sold 22,315 shares of 10x Genomics stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $307,723.85. Following the transaction, the chief financial officer owned 309,273 shares in the company, valued at $4,264,874.67. This trade represents a 6.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Benjamin J. Hindson sold 7,486 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the sale, the insider owned 440,888 shares of the company's stock, valued at $6,079,845.52. This represents a 1.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,149 shares of company stock worth $539,865. 9.39% of the stock is currently owned by insiders.

10x Genomics Stock Down 1.9%

TXG traded down $0.27 during trading hours on Friday, hitting $14.01. The stock had a trading volume of 1,566,109 shares, compared to its average volume of 3,076,602. The company's fifty day simple moving average is $12.92 and its 200 day simple moving average is $10.69. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $24.76. The stock has a market cap of $1.74 billion, a PE ratio of -20.01 and a beta of 2.03.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.63. The business had revenue of $172.91 million for the quarter, compared to analysts' expectations of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The firm's quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, equities analysts expect that 10x Genomics will post -1.43 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on TXG shares. UBS Group upped their price target on shares of 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Barclays reiterated an "overweight" rating and issued a $15.00 price objective (up from $13.00) on shares of 10x Genomics in a report on Friday, August 8th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 10x Genomics in a research report on Thursday, August 14th. Wall Street Zen raised shares of 10x Genomics from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Morgan Stanley reduced their price target on 10x Genomics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Tuesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, 10x Genomics presently has an average rating of "Hold" and a consensus price target of $13.54.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.